AstraZeneca faced a setback with the discontinuation of its volrustomig trial for non-small cell lung cancer, but strong clinical results for drugs like Tagrisso and Enhertu support its growth prospects. Investment firm CICC gave AstraZeneca an "Outperform" rating, highlighting its potential despite pipeline challenges. Citigroup also maintains a "buy" rating, citing AstraZeneca's leadership in cancer drug development and promising late-stage trial results. These developments suggest continued growth potential in AstraZeneca's cancer treatment portfolio.
AstraZeneca announced that its drug Tezspire met all primary and key secondary goals in a late-stage trial for eosinophilic esophagitis, a chronic condition causing inflammation and difficulty swallowing. The trial involved 368 patients who received ...
AstraZeneca has priced a €2.55 billion bond issuance split into four fixed-rate tranches maturing between 2030 and 2038. The bonds, issued by its US subsidiary and guaranteed by the parent company, carry coupons ranging from 3.402% to 4.169%, reflect...
